Advertisement


Danny Rischin, MD, on Squamous Cell Carcinoma: Treatment Trial Results

2018 ASCO Annual Meeting

Advertisement

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase II study findings on cemiplimab, a human monoclonal anti–PD-1 antibody, in patients with metastatic cutaneous squamous cell carcinoma (Abstract 9519).



Related Videos

Kidney Cancer
Immunotherapy

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss two treatment studies: one testing pegilodecakin with nivolumab or pembrolizumab and the other evaluating an oral CXCR4 inhibitor in combination with axitinib (Abstracts 4509 & 4510).

Kidney Cancer
Immunotherapy

David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (Abstract 4500).

Kidney Cancer

Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial

Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Daniel J. Margul, MD, PhD, on Cervical Cancer and Minimally Invasive Surgery

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Daniel J. Margul, MD, PhD, of Northwestern University, discuss the outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer (Abstract 5502).

Prostate Cancer

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).

Advertisement

Advertisement




Advertisement